ERBB2 and triple-negative breast carcinoma: There is Level 1B evidence that high levels of sTILs are associated with improved outcome and an enhanced response to neoadjuvant therapy in triple-negative and HER2-positive breast cancers7,11–14,29, and are prognostic for disease-free and overall survival in early triple-negative breast cancers treated with standard anthracycline-based adjuvant chemotherapy4,6,9.